WO2006078892A3 - Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy - Google Patents

Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy Download PDF

Info

Publication number
WO2006078892A3
WO2006078892A3 PCT/US2006/002020 US2006002020W WO2006078892A3 WO 2006078892 A3 WO2006078892 A3 WO 2006078892A3 US 2006002020 W US2006002020 W US 2006002020W WO 2006078892 A3 WO2006078892 A3 WO 2006078892A3
Authority
WO
WIPO (PCT)
Prior art keywords
psma
therapy
prostate specific
cancer
cancer diagnosis
Prior art date
Application number
PCT/US2006/002020
Other languages
French (fr)
Other versions
WO2006078892A2 (en
Inventor
Ayyappan K Rajasekaran
Original Assignee
Univ California
Ayyappan K Rajasekaran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Ayyappan K Rajasekaran filed Critical Univ California
Publication of WO2006078892A2 publication Critical patent/WO2006078892A2/en
Publication of WO2006078892A3 publication Critical patent/WO2006078892A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides, for the first time, the finding that a soluble extracellular domain of PSMA or a peptide fragment thereof specifically binds to PSMA-overexpressing, without any of the delivery problems or toxic side-effects associated with the use of such antibodies. In particular, the PSMA polypeptides and peptides described herein bind to PSMA on the surface of cells such as cancer cells and therefore have clinical significance for diagnosing, providing a prognosis for, imaging, and/or treating a cancer that overexpresses cell surface PSMA such as prostate cancer as well as endothelial cells of solid tumors. Compositions and kits for carrying out the methods of the present invention are also provided.
PCT/US2006/002020 2005-01-21 2006-01-19 Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy WO2006078892A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64593005P 2005-01-21 2005-01-21
US60/645,930 2005-01-21

Publications (2)

Publication Number Publication Date
WO2006078892A2 WO2006078892A2 (en) 2006-07-27
WO2006078892A3 true WO2006078892A3 (en) 2008-06-05

Family

ID=36692918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002020 WO2006078892A2 (en) 2005-01-21 2006-01-19 Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy

Country Status (1)

Country Link
WO (1) WO2006078892A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008538A (en) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods.
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AIELLO ET AL.: "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using double VEGF-receptor chimeric proteins", PROC. NATL. ACAD. SCI. USA, vol. 92, no. 23, 7 November 1995 (1995-11-07), pages 10457 - 10461 *
SCHULKE ET AL.: "The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy", PROC. NATL. ACAD. SCI. USA, vol. 100, no. 22, 28 October 2003 (2003-10-28), pages 12590 - 12595, XP002323660, DOI: doi:10.1073/pnas.1735443100 *

Also Published As

Publication number Publication date
WO2006078892A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2009029591A3 (en) Monoclonal antibody which binds met in formalin-fixed and paraffin-embedded tissues and related methods
WO2008045976A3 (en) Compositions and methods for treating and diagnosing cancers
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
ATE497508T1 (en) ANTIBODIES DIRECTED AGAINST THE MAMMAL EAG1 ION CHANNEL PROTEIN
TW200740847A (en) Polypeptides and antibodies
WO2008010101A3 (en) Antagonist antibody against epha2 for the treatment of cancer
WO2007109321A3 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
WO2008120202A3 (en) Antibodies, methods and kits for diagnosing and treating melanoma
WO2005104810A3 (en) Novel therapeutic targets in cancer
WO2008112269A3 (en) K-ras mutations and anti-egfr antibody therapy
JP2015533788A5 (en)
WO2008053330A3 (en) Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2009019365A3 (en) Ezrin assay method for the in vitro diagnosis of colorectal cancer
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007075921A3 (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
RU2015132142A (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMOR
MX2007004342A (en) Cop1 molecules and uses thereof.
WO2004060915A3 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2006078892A3 (en) Use of a novel prostate specific membrane antigen for cancer diagnosis and therapy
Murray et al. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types
WO2006038955A3 (en) Novel therapeutic targets in cancer
Bloch et al. The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06719001

Country of ref document: EP

Kind code of ref document: A2